OTCM
ECIA
Market cap4mUSD
Jul 10, Last price
0.37USD
1D
0.00%
1Q
-22.59%
Jan 2017
5.74%
Name
Encision Inc
Chart & Performance
Profile
Encision Inc., a medical device company, designs, develops, manufactures, and markets patented surgical instruments in the United States. The company provides active electrode monitoring (AEM) surgical instruments and monitors that enhance patient safety and patient outcomes in laparoscopic surgical procedures. Its AEM instruments product line comprises a range of endo-mechanical instruments, including scissors, graspers, and dissectors, as well as fixed-tip electrodes and suction-irrigation electrodes. The company also offers various handles, which are used for advanced laparoscopic procedures that incorporate stiffer shafts and ergonomic features; and AEM EndoShield 2 burn protection systems, as well as markets AEM monitor product line that is used in conjunction with AEM instruments. The company sells its products through a network of direct and independent sales representatives. Encision Inc. was incorporated in 1991 and is based in Boulder, Colorado.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | 2016‑03 | |
Income | |||||||||
Revenues | 6,586 -10.38% | 7,349 -4.16% | |||||||
Cost of revenue | 7,227 | 7,652 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (641) | (303) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 42 | ||||||||
Tax Rate | |||||||||
NOPAT | (641) | (345) | |||||||
Net income | (692) 89.01% | (366) -178.99% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | (30) | 21 | |||||||
BB yield | |||||||||
Debt | |||||||||
Debt current | 569 | 576 | |||||||
Long-term debt | 1,831 | 1,102 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | 2,358 | 1,489 | |||||||
Cash flow | |||||||||
Cash from operating activities | 144 | (861) | |||||||
CAPEX | (12) | (183) | |||||||
Cash from investing activities | (37) | (183) | |||||||
Cash from financing activities | (254) | 284 | |||||||
FCF | (378) | (819) | |||||||
Balance | |||||||||
Cash | 43 | 189 | |||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | 1,827 | 2,495 | |||||||
Invested Capital | 3,160 | 3,579 | |||||||
ROIC | |||||||||
ROCE | |||||||||
EV | |||||||||
Common stock shares outstanding | 11,770 | 11,763 | |||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | (556) | (216) | |||||||
EV/EBITDA | |||||||||
Interest | 62 | 21 | |||||||
Interest/NOPBT |